This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼(isatuximab) can be found via the Product Card at the bottom of the page.
In this video, you'll learn about
A case study presented by Dr Clark of a 72 year old RRMM patient who rapidly progressed through 3 lines of treatment in 5 years and experienced severe bone disease complications. The patient had concerns about 4th line treatment however received SARCLISA®+ Pd at 4th Line.
Overview of SARCLISA®
Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.
Dosing and Administration Guide
Download a handy guide to SARCLISA dosing and administration information.
Patient Booklet
Download SARCLISA® patient information.
Get in touch with the Oncology Team
Relapsed Refractory Multiple Myeloma Product
MAT-XU-2202571 (v1.0)
Date of Preparation: September 2023
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
